Approval Year
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
591617
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
||
|
NDF-RT |
N0000191260
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
||
|
NCI_THESAURUS |
C129822
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
OPDIVO (AUTHORIZED: MELANOMA)
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
670918
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
595817
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
||
|
NCI_THESAURUS |
C128037
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
NIVOLUMAB BMS( WITHDRAWN: CARCINOMA, NON-SMALL-CELL LUNG)
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
442614
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
595017
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
469615
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
641718
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
545016
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
445014
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
387612
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
489915
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
491415
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
595917
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
||
|
WHO-ATC |
L01XC17
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
||
|
FDA ORPHAN DRUG |
531016
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C551361
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
PRIMARY | |||
|
31YO63LBSN
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
PRIMARY | |||
|
9623
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
PRIMARY | |||
|
m11824
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
PRIMARY | |||
|
100000145087
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
PRIMARY | |||
|
4923
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
PRIMARY | |||
|
1597876
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
PRIMARY | RxNorm | ||
|
946414-94-4
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
PRIMARY | |||
|
SUB122750
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
PRIMARY | |||
|
7335
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
PRIMARY | |||
|
N0000191259
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
PRIMARY | Programmed Death Receptor-1-directed Antibody Interactions [MoA] | ||
|
31YO63LBSN
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
PRIMARY | |||
|
DB09035
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
PRIMARY | |||
|
CHEMBL2108738
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
PRIMARY | |||
|
YY-151
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
PRIMARY | |||
|
Nivolumab
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
PRIMARY | |||
|
Nivolumab
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
PRIMARY | |||
|
C68814
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
PRIMARY | |||
|
8256
Created by
admin on Sat Dec 16 02:27:53 GMT 2023 , Edited by admin on Sat Dec 16 02:27:53 GMT 2023
|
PRIMARY |
ACTIVE MOIETY